IP Verse

Blood-Based Biomarkers Of Tumor Sensitivity To Pd-1 Antagonists

Patent No. EP3283882 (titled "Blood-Based Biomarkers Of Tumor Sensitivity To Pd-1 Antagonists") was filed by Merck Sharp & Dohme on Apr 12, 2016. The application was issued on Oct 16, 2024.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
SYMBIOSIS IP LIMITEDSep 15, 2021SYMBIOSIS IP LIMITED

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP3283882

MERCK SHARP & DOHME
Application Number
EP16780526A
Filing Date
Apr 12, 2016
Status
Patent Maintained As Amended
Sep 13, 2024
Publication Date
Oct 16, 2024
External Links
Slate, Register , Google Patents